How pancreatic cancer blocks immunotherapy – BioNews Central Researchers have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer — and identified a promising strategy to overcome that resistance. ...

Researchers have uncovered a key reason why #immunotherapy has largely failed in #PancreaticCancer and have identified a promising strategy to overcome this resistance.
#PancreaticCancerTreatment #ImmunotherapyResistance

SITC knows the future of cancer IO depends on the next generation of investigators. Apply for SITC fellowships by April 15 for a chance to receive one year of research funding! Learn more: http://sitcancer.org/fellowships #SITCFellowship #immunotherapy #grant

Exciting discoveries in the gut biome's participation in immune response to cancer. #immunoengineering #immunology #immunotherapy

One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio Fourteen months after treatment with engineered immune cells, the recipient has no symptoms and doesn’t need to take medication.

'CAR-T therapy is typically used to treat blood cancers such as leukaemia, & it remains experimental for autoimmune conditions. June says, however, that he expects a wave of regulatory approvals of CART cells to treat autoimmune conditions, starting with lupus, myositis & scleroderma'
#Immunotherapy

Immune modulatory vaccines (IMVs) are an emerging class of #immunotherapy designed to expand anti-#Tregs that selectively target immunosuppressive elements within the TME. 💉

Learn more in Dr. Mads Hald Andersen's @sigtrans-sttt.bsky.social's paper:

📖: https://go.nature.com/4tZDxVp

🎓 Trainee travel award funding is available for the Inaugural IISFD Meeting in Crete, Greece 🇬🇷
Students and early-career researchers: apply today!
⏰ Deadline: April 15, 2026
🔗 aegeanconferences.org/conferences/...
#FungalDiseases #Immunotherapy

Researchers find new target to sensitize pancreatic tumors to immunotherapy Researchers find new target to sensitize pancreatic tumors to immunotherapy

Epigenetics News - Researchers find new target to sensitize pancreatic tumors to immunotherapy

News – bit.ly/4tHGBoX Study - bit.ly/41oVznK

#Epigenetics #Cancer #Immunotherapy
---

Gain deeper insights into gene regulation; epigenometech.com

April 10,2026

ALL GOOD THINGS…🥹

Thx🙏🏽 to the patients & so many amazing people @thenci & beyond in my 21+yrs

Many good Friends on the Journey

Dr. Melissa Abel continues the research:#PSMA+ #BCR & #cytokines #ProstateCancer #immunotherapy

The future @ NCI is bright☀️

The Painful Wait for Jonathan Franzen Culture and entertainment musts from Eleanor Barkhorn

CAR-T therapy is stepping beyond cancer and showing promise in autoimmune disease. A treatment once seen as niche could redefine how we fight multiple conditions. Real progress, real potential. #CancerResearch #Immunotherapy #TCSC
www.theatlantic.com/health/archi...

The May issue is now online!

👉 Read our latest articles:
onlinelibrary.wiley.com/toc/13652796...

#oncology #tumors #immunotherapy #epigenetic #T1D #pregnancy #HLA #CIPO #gastrointestinal #gaucher #GD1 #pheochromocytoma #paraganglioma #cholesterol #ColorectalCancer #screening #ataxia #ITPR1

✅ Demonstrates crosstalk between #Metabolism and #Immunity via ROS, OXPHOS & glutamine pathways 🔄⚡
✅ Suggests combining #NeddylationTargeting with #Immunotherapy for enhanced treatment outcomes 🎯💡

🚨 New Research on #CancerBiology #Immunotherapy #Neddylation 🧬🔥
A cutting-edge review uncovers how protein neddylation reshapes #AnticancerImmunity and tumor microenvironment dynamics! 🌍🧪

MoonLake Immunotherapeutics Form 144 Filing MoonLake filed a Form 144 on April 9, 2026; SEC Rule 144 triggers at 5,000 shares or $50,000, raising immediate liquidity questions for small-cap immunotherapy names.

MoonLake Immunotherapeutics Form 144 Filing: MoonLake filed a Form 144 on April 9, 2026; SEC Rule 144 triggers at 5,000 shares or $50,000, raising immediate liquidity questions for small-cap immunotherapy names. 👈 Read full analysis #MoonLake #Immunotherapy #Form144 #SEC #SmallCapStocks

Promotional banner with purple-blue microscopic cell background; white text reads “Meet our team at AACR 2026 in BOOTH #723” and the iRepertoire, Inc. logo appears in the lower-right.

The capabilities and services you need to gain greater insights into the patient immune response will be highlighted in booth #723 at AACR 2026!

Get a sneak peek of our immuno-oncology portfolio here:
irepertoire.com/immuno-oncol...

#AACR2026 #CancerResearch #ImmunoOncology #Immunotherapy

China PD-1 Immunotherapy Cost & Hospital Guide: An Objective Choice Understand the true cost of PD-1 immunotherapy in China, along with clinical data and eligibility. medbridgenz provides medical concierge assistance globally.

Is the cost of immunotherapy out of reach?
China’s PD-1 treatments (Toripalimab/Sintilimab) offer 70-85% savings vs. Western prices—often starting at just $1,500/cycle.

Read our 2026 Cost & Hospital Guide: zurl.co/TLxg0

#Immunotherapy #Oncology #ChinaMedicalTourism

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma | CancerNetwork The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Worth the read if you care about where lymphoma therapy is heading.

www.cancernetwork.com/view/rethink...

#OncTwitter #CAR-T #Lymphoma #Immunotherapy

Empowering Ovarian Cancer Immunotherapy. Aggressive ovarian cancers are deadly because they block a patient’s immune system. A new study demonstrates how this shield can be removed. #OvarianCancer #CancerResearch #Immunotherapy #MedicalBreakthrough #FutureMedicine

Happening on Friday!

🔗Register: hemehub.org/live-webinars
🔗Case submissions: hemehub.org/case-submiss...

#MultipleMyeloma #PlasmaCellDisorders #Hematology #Oncology #Immunotherapy #HEMEHUB @mskcancercenter.bsky.social @imfmyeloma.bsky.social @myeloma-society.bsky.social @themmrf.bsky.social

HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack Key Points. HLA-ESP-1C single chain trimer protects gene-edited (MHC-I/II/TCR/CD54/CD58 deficient) human allogeneic CAR T cells from lysis by NK cells.Univ

Generating universal allogeneic CART (UCART) cells that evade #NKcell “missing-self” response w/ similar performance to autologous #CARTCell in vitro/vivo doi.org/10.1182/bloo... #CellTherapy #ImmunoTherapy #TranslationalScience

#ESMORareCancers26: ARCAGEN highlights a gap between molecular profiling and treatment in advanced #RareCancers. Among patients with clinically actionable alterations, only 15% received matched targeted therapy or #immunotherapy.
#ESMODailyReporter 📌 https://ow.ly/bjjH50YFB8j

Preclinical data suggest an adaptable immune-cell therapy could bring fresh momentum to a bone disease field that’s barely changed in decades.

Link as first comment.

#longevity #geroscience #immunotherapy #osteosarcoma

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRwlYf
@ASCO

#SocialListening #LucidQuest

CAR T-Cell Therapy: Could a Cancer Breakthrough Cure Autoimmune Diseases? Roswell Park researchers have begun using CAR T-cell therapies for autoimmune diseases

CAR T-cell therapy is opening exciting new possibilities beyond cancer, with researchers now exploring how it could help treat autoimmune diseases too. Read more: www.roswellpark.org/newsroom/202... #CARt #Immunotherapy #AutoimmuneDisease #TCSC

Prize winner’s research reprograms tumor cells to trigger antitumor immunity | American Association for the Advancement of Science (AAAS)

For his work towards developing a novel cancer #immunotherapy that turns tumors into their own vaccines, Dr. Fábio Rosa has received the 2026 BioInnovation Institute & Science Prize for Innovation. 💉

Congratulations! 🤩

🗞️Learn more: https://bit.ly/4t8LvLu | @aaas.org

Now accepting your Letter of Intent (LOI) for a #SITCFellowship. There is $150,000 in research funding available for early career investigators who apply. Learn more and take the next step to funding here: http://sitcancer.org/fellowships #ECR #Immunotherapy

⏰ Reminder: Join the Inaugural Meeting of the Int'l Immunotherapy Society for #Fungal #Diseases (IISFD) in Crete, Greece 🇬🇷
Submit your abstract and apply for the trainee travel award by April 15, 2026! 🧫
Info: aegeanconferences.org/conferences/...
#Immunotherapy #FungalDiseases #AcademicConferences

How mRNA and Neoantigen Technologies Are Transforming the Cancer... Cancer immunotherapy has significantly transformed the treatment landscape by introducing innovative approaches that leverage the body’s immune system to fight malignant cells. Among these, cancer vac...

How mRNA and Neoantigen Technologies Are Transforming the Cancer Vaccines Market

Source: www.panchit.com/blogs/5068/H...

#CancerVaccines #OncologyResearch #Immunotherapy #CancerTreatment

Ross' Story In 2015, Ross was diagnosed with stage 2A cutaneous melanoma and underwent wide local excision (WLE) and sentinel lymph node biopsy (SLNB) treatment.

Ross is sharing his story to remind others to stay vigilant and to offer hope to those facing melanoma:

“To never give up… I have seen miraculous things happen.”

You can read his full story HERE: bit.ly/PatientStory...

#MelanomaFocus #PatientStory #SkinCancerAwareness #Immunotherapy #Hope(5/5)

Happening this Friday!

🔗Register: hemehub.org/live-webinars
🔗Case submissions: hemehub.org/case-submiss...

#MultipleMyeloma #Hematology #Oncology #MedicalEducation #PatientCare #Immunotherapy #CellTherapy #NovelTherapies #ClinicalTrials #HemeHub
@mskcancercenter.bsky.social

Personalized Cancer Vaccines Just Hit 5-Year Durability — Here's the Catch Personalized mRNA cancer vaccines show 49% reduction in recurrence at 5 years. Here's how they work, who's behind them, and when patients will actually get acce

49% reduction at five years is the kind of number that actually changes treatment protocols.